The resistance of low density lipoprotein to oxidation promoted by copper and its use as an index of antioxidant therapy

被引:35
作者
OLeary, VJ [1 ]
Tilling, L [1 ]
Fleetwood, G [1 ]
Stone, D [1 ]
DarleyUsmar, V [1 ]
机构
[1] WELLCOME RES LABS,BECKENHAM BR3 3BS,KENT,ENGLAND
关键词
atherosclerosis; Watanabe rabbits; LDL oxidation; probucol;
D O I
10.1016/0021-9150(95)05644-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The measurement ex vivo of the resistance of low density lipoprotein (LDL) to oxidation promoted by copper is now being used in surveys of human populations at risk of developing atherosclerosis. However, it is not known whether a relationship between LDL oxidisability measured in this way and the development of atherosclerotic lesions exists. Using Watanabe rabbits as a model of the disease, we have found that dietary supplementation with the antioxidants, probucol and a-tocopherol, increased the resistance of LDL isolated from small volumes of plasma to oxidation. The antioxidant effects of probucol incorporated into LDL through dietary supplementation were greater than when incorporated ex vivo. When dietary supplementation was extended to a period of three months; the well established anti-atherosclerotic effects of probucol were confirmed and a highly significant relationship between the probucol content of the LDL particle and the extent of the atherosclerotic lesion in the aorta emerged. These results suggest that the assessment of the resistance of LDL isolated from plasma to oxidation promoted by copper may reflect the response of the arterial atherosclerotic process to antioxidant therapy.
引用
收藏
页码:169 / 179
页数:11
相关论文
共 50 条
[31]   The inhibition of low density lipoprotein oxidation by 17-alpha estradiol [J].
Dittrich, R ;
Müller, A ;
Hensen, J ;
Wildt, L .
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 1999, 107 (01) :53-57
[32]   Effect of vitamin E on low density lipoprotein oxidation at lysosomal pH [J].
Alboaklah, Hadeel K. M. ;
Leake, David S. .
FREE RADICAL RESEARCH, 2020, 54 (8-9) :574-584
[33]   Oxylipin profile of human low-density lipoprotein is dependent on its extent of oxidation [J].
Surendran, Arun ;
Zhang, Hannah ;
Winter, Tanja ;
Edel, Andrea ;
Aukema, Harold ;
Ravandi, Amir .
ATHEROSCLEROSIS, 2019, 288 :101-111
[34]   Iron as a catalyst of human low-density lipoprotein oxidation: Critical factors involved in its oxidant properties [J].
Lapenna, Domenico ;
Ciofani, Giuliano ;
Obletter, Gabriele .
JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY, 2017, 41 :111-118
[35]   Influence of fish oil supplementation on in vivo and in vitro oxidation resistance of low-density lipoprotein in type 2 diabetes [J].
H Pedersen ;
M Petersen ;
A Major-Pedersen ;
T Jensen ;
N S Nielsen ;
S T Lauridsen ;
P Marckmann .
European Journal of Clinical Nutrition, 2003, 57 :713-720
[36]   Influence of fish oil supplementation on in vivo and in vitro oxidation resistance of low-density lipoprotein in type 2 diabetes [J].
Pedersen, H ;
Petersen, M ;
Major-Pedersen, A ;
Jensen, T ;
Nielsen, NS ;
Lauridsen, ST ;
Marckmann, P .
EUROPEAN JOURNAL OF CLINICAL NUTRITION, 2003, 57 (05) :713-720
[37]   Comparative studies on the antioxidant activities of nine common food legumes against copper-induced human low-density lipoprotein oxidation In Vitro [J].
Xu, B. J. ;
Yuan, S. H. ;
Chang, S. K. C. .
JOURNAL OF FOOD SCIENCE, 2007, 72 (07) :S522-S527
[38]   Effects of oolonghomobisflavan A on oxidation of low-density lipoprotein [J].
Sukhbold, Enkhtsetseg ;
Sekimoto, Shogo ;
Watanabe, Emiko ;
Yamazaki, Akane ;
Yang, Lifeng ;
Takasugi, Mikako ;
Yamada, Koji ;
Hosomi, Ryota ;
Fukunaga, Kenji ;
Arai, Hirofumi .
BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, 2017, 81 (08) :1569-1575
[39]   THE EFFECT OF EDTA ON THE OXIDATION OF LOW-DENSITY-LIPOPROTEIN [J].
LAMB, DJ ;
LEAKE, DS .
ATHEROSCLEROSIS, 1992, 94 (01) :35-42
[40]   Combined oestrogen-progestogen replacement therapy does not inhibit low-density lipoprotein oxidation in postmenopausal women [J].
Wen, YC ;
Doyle, MCT ;
Norris, LA ;
Sinnott, MM ;
Cooke, T ;
Harrison, RF ;
Feely, J .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 47 (03) :315-321